文献速递白血病

CEBPA bZIP 特征在细胞遗传学正常急性髓系白血病中的预后价值

Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2025-05-26

该研究纳入141例CEBPA bZIP框内突变(CEBPAbZIP-inf)的急性髓系白血病患者,发现bZIP突变的变异等位基因频率(VAF)和碱基改变数与累积复发率(CIR)相关,结合白细胞计数和首次巩固后可测量残留病可将患者分为低、中、高危三个亚组,中危和高危患者可从移植中降低复发率,但仅高危患者总生存获益,作者建议高危患者移植、低危和中危患者巩固化疗。

要点

  • VAF高 vs 低:CIR 74.0% vs 27.0%(p < 0.001)。
  • bZIP突变碱基改变≤3 vs >3个:CIR 39.1% vs 60.6%(p = 0.042)。
  • 低、中、高危组CIR分别为15.2%、47.1%、83.0%(p < 0.001)。

核心结论

  • CEBPAbZIP-inf患者存在异质性,bZIP特征可影响风险分层,作者建议采用风险适配的治疗模式。
  • 作者推荐高危患者接受移植,低危和中危患者接受巩固化疗。

研究设计与样本

  • 研究纳入141例CEBPAbZIP-inf的急性髓系白血病患者。
  • 分析bZIP突变的变异等位基因频率(VAF)和碱基改变与累积复发率(CIR)的关联。

主要发现

  • VAF高 vs 低:CIR 74.0% vs 27.0%(p < 0.001)。
  • bZIP突变碱基改变≤3 vs >3个:CIR 39.1% vs 60.6%(p = 0.042)。
  • VAF、碱基改变、白细胞计数和首次巩固后可测量残留病可将患者分为低、中、高危三个亚组,CIR分别为15.2%、47.1%、83.0%(p < 0.001)。
  • 中危患者移植 vs 未移植复发率11.6% vs 49.7%(p = 0.009),高危患者5.6% vs 84.1%(p < 0.001),低危患者0% vs 15.2%(p = 0.220)。
  • 仅高危患者移植 vs 未移植总生存100% vs 59.7%(p = 0.003)。

临床怎么用

  • 作者推荐高危患者接受移植。
  • 作者推荐低危和中危患者接受巩固化疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent studies revealed that CEBPA with basic leucine zipper (bZIP) in-frame mutation (CEBPAbZIP-inf) is the bona fide entity with a favourable prognosis in acute myeloid leukaemia. However, the mechanism by which the bZIP signatures influence risk stratification remains unclear. We identified 141 patients with CEBPAbZIP-inf. Variant allele fraction (VAF) (cumulative incidence of relapse [CIR], VAFhigh vs. VAFlow, 74.0% vs. 27.0%, p < 0.001) and base change (≤ vs. >3 bases, 39.1% vs. 60.6%, p = 0.042) of bZIP mutations were associated with CIR. These two factors, along with the white blood cell count and measurable residual disease after first consolidation, could stratify patients into three risk subgroups (CIR, low vs. medium vs. high risk, 15.2% vs. 47.1% vs. 83.0%, p < 0.001). Compared with no transplantation, receiving a transplantation significantly decreased the relapse rates in medium-risk (transplantation vs. no transplantation, 11.6% vs. 49.7%, p = 0.009) and high-risk patients (5.6% vs. 84.1%, p < 0.001) but not low-risk (0% vs. 15.2%, p = 0.220). However, only high-risk patients could benefit from transplantation in terms of overall survival (100% vs. 59.7%, p = 0.003). Our study revealed the heterogeneity of CEBPAbZIP-inf patients and suggested a risk-adapted treatment modality. Transplantation is recommended for high-risk patients and consolidation chemotherapy is recommended for low-risk and medium-risk patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wu LX, Liao MY, Zhao MY, et al. Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia. Br J Haematol. 2025. PMID: 40419412. doi:10.1111/bjh.20164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。